Polynovo
- Short interest
- 7.29%
- −0.62 pp 30d
- as of 12 Oct 2026
- Reported shorts
- 50.4M
- Shares on issue
- 690.843M
Polynovo (PNV) Short Interest
Polynovo (ASX:PNV) had 7.29% of shares reported as short positions as of 12 Oct 2026, representing 50,368,240 shares. Polynovo operates in the Health Care Equipment & Services industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Polynovo
PolyNovo specializes in developing and commercializing advanced medical devices using its proprietary NovoSorb technology. The company focuses on treating burns, surgical wounds, and providing solutions for Negative Pressure Wound Therapy, positioning itself as a leader in innovative healthcare solutions.
Company profile →Polynovo (ASX:PNV) has 7.29% of its shares on issue reported as short positions as of 12 Oct 2026, or about 50,368,240 shares. Over the past 30 days that figure has fallen 0.62 percentage points, and over 90 days it has fallen 1.40 percentage points. Its highest recorded short interest was 14.61% in May 2026. PNV is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads PNV today
- Zanger BreakoutWatchScore 19rank 1202 of 1893
- CAN SLIMWatchScore 7rank 1400 of 1549
- Minervini Trend TemplateWatchScore 7rank 1488 of 1684
- Crowded-Short BreakoutSetupScore 39rank 53 of 1448
- Quality compoundersWatchScore 44rank 187 of 1660
Prices to 15 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
PNV fundamentals
In the year to 30 Jun 2026, Polynovo (ASX:PNV) recorded revenue of A$143.7M and net profit after tax of A$7.3M. A year earlier it recorded revenue of A$127.2M and net profit after tax of A$13.2M. Year-on-year growth: revenue +12.9% (FY), EPS −44.4% (FY). Net margin 5.1%, return on equity 8.4% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest PNV news
All news- Why PolyNovo Fell Even As Sales Rose - Simply Wall Street
googlenews · 9 Oct 2026
- Can PolyNovo (ASX:PNV) Keep Its Wound-Care Growth Running?
kalkine · 9 Oct 2026
- PolyNovo Notice of Annual General Meeting
asx · 27 Sept 2026
Company details
website
address
More Health Care Equipment & Services Stocks
Other shorted stocks in this sector
Be the first to discuss PNV
Start a research thread or post the first pulse update